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S U M M A R Y
The introduction of ﬁrst-generation protease inhibitors for the treatment of chronic hepatitis C in
subjects infected with hepatitis C virus (HCV) genotype 1 has signiﬁcantly improved the sustained
virological response (SVR) rate. As liver cirrhosis reduces the probability of achieving SVR, current
guidelines discourage response-guided therapy in cirrhotic patients. We report the ﬁrst case of a
cirrhotic woman with chronic HCV and HIV co-infection achieving virological response after an ultra-
short course of therapy. A 40-year-old HIV/HCV co-infected woman with compensated liver cirrhosis
was treated with anti-HCV triple therapy containing telaprevir plus pegylated interferon and ribavirin.
Baseline plasma HCV RNA was 3.6 log IU/ml and transaminases were within the normal range. She
harboured IL28B rs12979860 C/C alleles. Ten days after starting therapy, the patient stopped treatment
because of mild anorexia and nausea. Virological response was detected at treatment discontinuation
and was maintained up to 24 weeks. This case describes an unexpected SVR after a 10-day course of
antiviral therapy in a cirrhotic HIV/HCV co-infected woman presenting positive predictive factors for a
response (low viral load, IL28B genotype). Nonetheless, there is no evidence to suggest a shorter duration
of treatment in this subset of patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Chronic hepatitis C virus (HCV) infection is responsible for
signiﬁcant morbidity and mortality worldwide, by determining
liver cirrhosis and subsequent end-stage liver disease and
hepatocellular carcinoma. Following the introduction of antire-
troviral therapy and the improvement in survival of patients with
HIV infection, chronic hepatitis C has assumed growing impor-
tance in this population. The recent introduction of ﬁrst-
generation protease inhibitors (PIs) boceprevir and telaprevir
in addition to the combination of pegylated interferon (PEG-IFN)
and ribavirin has led to a 30% increase in the sustained virological
response (SVR) rate in treatment-naive patients infected with
HCV genotype 1.1,2* Corresponding author. Tel.: +39 02 2643 7945; fax: +39 02 2643 7030.
E-mail address: hasson.hamid@hsr.it (H. Hasson).
http://dx.doi.org/10.1016/j.ijid.2014.08.011
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Different factors are associated with a better response to
treatment, such as HCV genotype, baseline viral load, rapid
virological response (RVR), CD4 count, insulin resistance, age,
obesity, ﬁbrosis stage, and the host’s interleukin-28B (IL28B)
genotype.2 Previous studies have shown that patients with a
favourable IL28B genotype achieving RVR obtain similar rates of
SVR even with a shorter duration of triple therapy.3 Nonetheless,
little information is available regarding cirrhotic persons living
with HIV co-infection.
Clinical trials in the HIV/HCV co-infected population suggest
that the safety proﬁle of HCV PIs, especially severity and frequency
of adverse events, are similar to those observed in HCV mono-
infected subjects,1 but their use may be complicated by the
potential drug–drug interactions with antiretroviral (ARV) drugs.2
Current data support the use of boceprevir or telaprevir in co-
infected patients with high CD4 cell counts not on ARV therapy and
in those on selected ARV regimens. For HIV-positive subjects co-
infected with HCV genotype 1, current guidelines suggest tripleciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Table 1
Plasma HCV-RNA and liver ﬁbrosis over time
HCV-RNA,
log IU/ml
FIB-4 APRI Liver
stiffness, KPa
Baseline 3.6 1.79 0.67 20.0
End of treatment <1.1 4.50 1.56
Week 12 post-treatment <1.1 1.37 0.41
Week 24 post-treatment <1.1 1.10 0.32 12.0
HCV-RNA, HCV plasma load; APRI, aspartate aminotransferase to platelet ratio
index.
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12 weeks of treatment followed by double therapy for 36 weeks
in the case of virological response.2 Nonetheless, the management
of triple therapy with telaprevir or boceprevir is particularly
challenging in cirrhotic patients, who are more prone to develop
adverse events,4 and requires even more attention in the presence
of concomitant HIV infection for the potential drug–drug inter-
actions with ARV and higher incidence of adverse events.5
2. Case report
We describe a case of HCV clearance after ultra-short triple
therapy with telaprevir plus PEG-IFN/ribavirin in a 40-year-old
cirrhotic woman, co-infected with HIV-1 (stage B3 according to
the Centers for Disease Control and Prevention (CDC) classiﬁca-
tion, 1993) and HCV genotype 1c, both diagnosed 19 years ago.
Her body mass index was 19.71 kg/m2. She reported previous
intravenous drug abuse, discontinued 10 years before. Liver
cirrhosis had been conﬁrmed by liver biopsy 15 years before.
Nonetheless, the patient had previously refused antiviral therapy
for HCV. After experiencing different ARV regimens (nadir CD4+
count 113 cells/mm3) mainly because of low tolerability and poor
compliance, she had been on stable ARV therapy with a boosted
PI-based regimen (tenofovir/emtricitabine plus atazanavir/rito-
navir) for 6 years thanks to the low pill burden and once-daily
dosing.
She was included in an Early Access Program (EAP) using
telaprevir (750 mg three times daily) + PEG-IFN alfa-2a (180 mg/
week) + weight-based ribavirin (1000 mg/day). Her baseline CD4+
cell count was 309 cells/mm3 (32.5%) with plasma HIV-RNA <37
copies/ml. At baseline, liver stiffness was 20.9 KPa and indirect
biochemical markers of liver ﬁbrosis APRI (aspartate aminotrans-
ferase to platelet ratio index) and FIB-4 were 0.67 and 1.74,
respectively. An abdominal ultrasound showed mild hepatomega-
ly with irregular margins and surface, and patchy parenchyma in
the absence of focal lesions, while no splenomegaly or other signs
of portal hypertension were recorded. No oesophageal varices
were observed endoscopically. Child–Turcotte–Pugh stage was A6.
She harboured IL28B rs12979860 C/C alleles.
At baseline, HCV-RNA was 3.6 log IU/ml (Abbott Real-Time HCV
Assay; detection limit <1.1 log IU/ml) and transaminases and
creatinine were within the normal range. The white blood cell
count was 3.2  109/l, haemoglobin 13.2 g/dl, and platelet count
116  109/l. The only adverse events experienced by the patient
were mild anorexia and nausea. Ten days after starting therapy, the
patient voluntarily interrupted PEG-IFN, ribavirin, and telaprevir,
maintaining ARV therapy.
At treatment discontinuation, liver enzymes were normal and
HCV-RNA <12 IU/ml. This undetectable HCV was maintained up to
24 weeks post-treatment. Indirect ﬁbrosis biomarkers and liver
stiffness showed a signiﬁcant improvement from baseline to
24 weeks after treatment completion (Table 1).
3. Discussion
We report a case of HCV clearance after only 10 days of triple
antiviral treatment. This observation shows the high virological
efﬁcacy of ﬁrst-generation PIs, leading to very early undetectable
HCV-RNA in this HIV co-infected cirrhotic woman with favourable
predictors for a virological response. SVR after this ultra-short
therapy also improved liver ﬁbrosis, apparently reversing bio-
chemical and ‘elastometric’ cirrhosis. Nonetheless, regular moni-
toring of liver disease and screening for its complications remains
essential in this subject.
Our patient presented a key factor associated with a poor
response to antiviral therapy, i.e., liver cirrhosis, together withother factors associated with a favourable response to treatment,
i.e., IL28B genotype CC, the absence of insulin resistance or
metabolic syndrome, and a low baseline viral load. The latter in
particular may represent the key factor explaining the HCV
clearance.2
Current guidelines do not consider the use of response-guided
therapy in the setting of liver cirrhosis and HIV infection,2 even
though this could be attractive since a signiﬁcantly higher
incidence of adverse events has been observed in HIV-infected5
and in cirrhotic subjects.4 Nonetheless, our observation represents
a single case of an unexpectedly positive response to an ultra-short
treatment schedule in a patient with many factors that positively
affected the probability of achieving a virological response.
Treatment shortening, even with response-guided therapy, is
not advisable in cirrhotic patients, since the advanced liver ﬁbrosis
and the reduced liver function are major obstacles to this goal, and
the achievement of SVR in this subset of patients represents a
major prognostic goal. Even though an adequate characterization
of host and viral factors associated with the response to antiviral
therapy would help clinicians to predict the maintenance of
virological response after premature treatment discontinuation for
adverse events, which is frequently observed in this group of
patients, this evaluation must not be carried out to select
candidates who would beneﬁt from a shorter duration of
treatment. Both baseline and on-treatment factors associated
with virological response should be evaluated and combined to
assess the overall probability of a response to treatment.
To conclude, this single observation must not lead to the
consideration of a shorter treatment duration in cirrhotic patients,
who deserve to receive the best treatment regimen in order to
achieve SVR and improve their prognosis. Rigorous clinical studies
in cirrhotic patients with favourable predictors of a virological
response are needed to evaluate the efﬁcacy and safety of shorter
treatment regimens.
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